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Objectives. It is unknown whether a therapeutic combination of
aspirin (ASA) and ticlopidine might effectively decrease activation
of hemostasis.
Background. Percutaneous transluminal coronary angioplasty
(PTCA), rotational atherectomy and stent implantation are pro-
cedures that fracture or ablate endothelium and plaque, a situa-
tion that activates hemostasis.
Methods. In 85 patients undergoing PTCA for a 77.8 6 1%
stenosis, we measured markers of coagulation and platelet acti-
vation (thrombin-antithrombin complexes [TAT], prothrombin
fragment 1 1 2 [F112] serotonin and the presence of circulating
activated platelets reacting with monoclonal antibodies against
glycoproteins exposed on platelet membranes). Blood samples
were drawn from a peripheral vein and from the coronary ostium
before the procedures. Both immediately and 10 min after angio-
plasty, and 10 min afterward, samples were collected from a
probing catheter (0.018 in. [0.46 cm]) positioned beyond the
stenosis. All patients were being treated with antianginal drugs
and ASA, 250 mg/day. Seventy of them had taken ticlopidine,
250 mg, twice daily for <21 day (<224 h) (n 5 28) or for >23 days
(>272 h) (n 5 42). Heparin (150 U/kg) was administered before
angioplasty. Thirty patients underwent PTCA; 15 of them were not
treated with ticlopidine and 15 were given ticlopidine (>272 h).
Thirty-five patients had stent implantation, 20 rotational atherec-
tomy.
Results. Before and during the procedures, there was greater
thrombin generation (expressed by higher TAT and F112 plasma
levels) in patients not taking ticlopidine or taking it for <224 h
(p < 0.05). Platelet activation and plasma serotonin levels were
also significantly higher in the no ticlopidine or <224-h ticlopidine
groups.
Conclusions. The combined use of ticlopidine, ASA and heparin
effectively controls activation of coagulation in patients with
stable or unstable angina undergoing coronary dilation.
(J Am Coll Cardiol 1997;29:13–20)
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Percutaneous transluminal coronary angioplasty (PTCA) is an
alternative procedure to surgical revascularization in the pres-
ence of atherosclerotic coronary artery disease (1,2). Rota-
tional atherectomy (3) and stent implantation (4,5) further
expand PTCA indications to calcified inelastic plaques and to
complicated irregular lesions. PTCA produces endothelial
desquamation, splitting of the atheromatous plaque, dissec-
tions and fibrous tissue rupture (6). The abrasion of the
endothelium and the rupture of the plaque expose fatty plaque
(which contains tissue factor) and smooth muscle to platelets,
inducing activation of the hemostasis system (2,7–11). The
generation of thrombin and the intracoronary deposition of
activated platelets may be responsible for acute and subacute
thromboses that limit the immediate and short-term success of
PTCA (1,2,7–9,12). In addition, serotonin locally released
from the dense granules of the circulating activated platelets is
thought to contribute to post-PTCA coronary vasoconstriction
(13). Clinical studies with intracoronary injection of serotonin
suggest that serotonin affects coronary artery tone (14,15), its
vasoconstrictor or vasodilator effect being dependent on the
presence of a normal endothelium (9,10,14,15). We (16) have
previously reported that alpha-adrenergic receptor antagonists
are able to counteract post-PTCA coronary vasoconstriction.
Patients undergoing angioplasty are usually treated with
heparin and aspirin (ASA) (1–3). ASA (17–19) inhibits the
prostaglandin G/H synthase, ultimately reducing the formation
of thromboxane A2, whereas heparin (20), acting as a cofactor,
enhances antithrombin III activity against thrombin. Despite
this antithrombotic regimen, acute and subacute thromboses
remain a problem in the outcome of PTCA (4,5,8,9,12). With
the advent of new devices, such as stents that fracture and the
Rotablator, which completely obliterates endothelium, plaque
and smooth muscle cells or sometimes the adventitia, effective
and safe antithrombotic strategies are needed to avoid acute
occlusion without causing bleeding complications (3–5,21).
In this study we investigated the degree of platelet and
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coagulation activation in coronary artery blood samples ob-
tained during dilation procedures to test the hypothesis that
the addition of a second antiplatelet drug such as ticlopidine
(22) might further attenuate platelet activation and plasma
serotonin release and consequently attenuate post-PTCA dis-
tal vasoconstriction (13).
Methods
Patient selection. We enrolled in the study 85 patients (67
men, mean age 6 SD 63.8 6 10 years) with documented
myocardial ischemia who were undergoing PTCA for signifi-
cant stenoses of major epicardial vessels (mean 6 SEM
stenosis 77.8 6 1%). Patients were included in the study after
giving informed written consent. They had no major diseases
other than angina pectoris. Sixty-five patients had unstable
angina. Twenty of the 30 patients undergoing conventional
angioplasty had stable angina and were considered to be at
lower thrombosis risk; 15 of these were not treated with
ticlopidine. Five of the 15 patients of the PTCA group had
unstable angina and consequently were given full antianginal
treatment and ticlopidine for $72 h. In these five patients with
unstable angina no stents were implanted because balloon
dilation gave a satisfactory result. Forty-eight patients had
significant stenosis of the left anterior descending coronary
artery, 12 of the left circumflex coronary artery, 23 of the right
coronary artery and 2 of the left main trunk.
Study protocol. The protocol was approved by the Clinique
Pasteur Ethical Committee and is summarized in Figure 1. All
patients were pretreated with calcium channel antagonists
(diltiazem, 180 to 360 mg/day), intravenous, oral or topical
nitrates and ASN (250 mg/day) starting $10 days before
PTCA. Patients who underwent rotational ablation or stent
implantation were given a beta-adrenergic blocking agent
(atenolol, 50 to 100 mg/day).
Dilation procedure. Neuroleptic analgesia with droperidol
(2 to 10 mg intravenously) and phenoperydine (0.6 to 1 mg
intravenously) was administered during the PTCA procedure
according to the standard protocol of the Clinique Pasteur
(16). With the patient under local anesthesia obtained with 1%
xylocaine, we cannulated a radial artery with a 6F sheath (35
patients) or a femoral artery with either 6F or 8F sheaths (50
patients).
Selective coronary visualization of the stenotic vessel was
obtained in two projections to provide the most accurate
evaluation of the stenotic region avoiding visual vessel over-
lapping. The same projections were subsequently repeated
soon after and 15 min after the dilation procedures to docu-
ment vasoconstriction (13,16,23). The angiographic images
were acquired with a Philips-DCI single-plane system at a cine
rate of 25 frames/s, with a 6.5-in. (16.5 cm) image intensifier
mode. Meglumine ioxaglate (64 g iodine/200 ml) was used as a
nonionic contrast medium. At the beginning of the PTCA
procedure a 0.014-in. (0.36 cm) guide wire was inserted far
beyond the stenosis and left in place throughout the study. A
0.018-in. (0.46 cm) 300-cm long guide wire was used in
Gianturco-Roubin stent implantation. A 0.009 guide wire was
inserted in rotational ablation.
PTCA was performed by standard technique using a mono-
rail balloon catheter system that provided the fastest catheter
exchange and insertion of a probing catheter for drawing blood
samples. Heparin (150 U/kg) was administered intravenously
at the beginning of the procedure, to keep the clotting time
.300 s (24). The activated clotting time was measured 10 and
Abbreviations and Acronyms
ASA 5 aspirin
F112 5 prothrombin fragment 1 1 2
ISDN 5 isosorbide dinitrate
PGE1 5 prostaglandin E1
PTCA 5 percutaneous transluminal coronary angioplasty
TAT 5 thrombin-antithrombin
Figure 1. Chart of study protocol. anti-CD62 and anti-
CD63 5 positive platelet activation; Bas 5 basal; Cor 5
coronary; Dist 5 distal; F 112 5 prothrombin fragment
112; Immediat 5 immediately; No T 5 no ticlopidine;
PTCA 5 percutaneous transluminal coronary angio-
plasty; ROTA 5 Rotablator; Serotonin 5 plasma sero-
tonin levels; T 5 ticlopidine; TAT 5 thrombin-
antithrombin complexes.
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60 min after heparin injection, that is, at the beginning and at
the end of the procedure. Patients with unstable angina
undergoing stent implantation or rotational atherectomy were
treated before the procedure with intracoronary injection of
1 mg of linsidomine (Corvasal, Hoechst 1 mg vials), a nitrous
oxide donor, and 3 mg of isosorbide dinitrate (ISDN). Re-
peated 3-mg doses of ISDN were injected during the proce-
dure for patients treated with rotational atherectomy (up to
9 mg) (Table 1). Patients undergoing conventional PTCA were
not given nitrates during the procedure (Table 1).
The number of inflations, the amount of pressure (atm) and
manipulation of the Rotablator were determined by the oper-
ator. One or multiple stents (Gianturco-Roubin or Palmaz-
Schatz) were implanted in vessels with a diameter .3.0 mm
and were overexpanded as compared with the nominal vessel
diameter to obtain a satisfactory result by covering the culprit
lesion and properly reconstructing the coronary artery seg-
ment. Immediately after the last deflation of the balloon, a
probing catheter (Cook or Schneider 3F) was quickly inserted
through the tip of the monorail side and positioned in the
dilated vessel beyond the stenosis to gently collect blood
samples through the 0.018-in. lumen.
Blood sampling. After heparin had been injected, basal
blood samples were collected first from a peripheral vein,
without a tourniquet, using a 19-gauge needle (Bas Vein).
Subsequently, the guiding catheter was positioned at the
coronary ostium and the guide wire was inserted into the distal
coronary artery. At this time a basal blood sample was drawn
from the coronary ostium. Two different precooled plastic
syringes were used for each sample. Immediately after collec-
tion the blood was placed in two ice-chilled plastic tubes, one
containing EDTA, imipramine, prostaglandin E1 (PGE1) and
theophylline, used for plasma serotonin measurements (13,25),
and one containing sodium citrate, used for coagulation mea-
surements and to assess platelet activation after incubation of
whole blood with monoclonal antibodies (9:1 vol/vol). After
angioplasty, blood samples were obtained from the dilated
coronary vessel with a 0.018-in. probing catheter positioned
beyond the lesion and from the proximal coronary artery
pulling back and washing the probing catheter. Blood samples
were also collected 10 min after the dilation procedures. The
protocol is summarized in Figure 1. All laboratory measure-
ments were performed without knowledge of patient data.
Measurement of platelet activation. With flow cytometry
one can detect in vivo platelet activation after the reaction of
citrated whole blood with monoclonal antibodies (26–28)
directed toward glycoproteins exposed on activated platelets.
Two monoclonal antibodies reacting with CD62 and CD63

















PTCA 15 2.72 6 0.2 0.67 6 0.1 75 6 3 PTCA 2.20 6 0.2 1.50 6 0.2* 230 6 3*
Distal 15 2.02 6 0.2 $72 h T 1.92 6 0.2 1.71 6 0.2* 216.3 6 2*
Control 10 2.15 6 0.2 No ISDN 2.10 6 0.2 1.80 6 0.2* 216.3 6 2*
PTCA 15 2.83 6 0.2 0.62 6 0.1 78 6 2 PTCA 2.29 6 0.2 1.63 6 0.2* 227 6 2*
Distal 15 2.08 6 0.2 No T 2.14 6 0.2 1.73 6 0.2* 217.4 6 2*
Control 12 2.13 6 0.1 No ISDN 1.97 6 0.1 1.20 6 0.1* 215.5 6 2*
PTCA 10 2.76 6 0.1 0.55 6 0.1 79 6 3 Rotablator 2.1 6 0.1 1.32 6 0.13* 237 6 6*
Distal 10 1.82 6 0.2 $72 h T 1.86 6 0.6 1.61 6 0.2* 216.6 6 3.1*
Control 9 2.55 6 0.3 ISDN, 3 1 6 mg 2.646 1.0 2.27 6 0.3* 216.3 6 1.7*
PTCA 10 2.57 6 0.1 0.52 6 0.5 79 6 1 Rotablator 2.11 6 0.1 1.46 6 0.1* 231 6 2*
Distal 10 1.75 6 0.1 #24 h T 2.01 6 0.1 1.58 6 0.1* 215.24 6 3.1*
Control 10 1.96 6 0.1 ISDN, 3 1 6 mg 2.156 0.1 1.75 6 0.2* 211.2 6 2.1*
PTCA 17 3.20 6 0.2 0.75 6 0.1 77 6 2 Stenting 3.02 6 0.1 2.81 6 0.1* 27.3 6 2*
Distal 17 2.28 6 0.2 $72 h T 2.21 6 0.2 1.92 6 0.1* 213.9 6 2.8*
Control 10 2.24 6 0.3 ISDN, 3 mg 2.34 6 0.2 2.09 6 0.3* 27.15 6 3.5
PTCA 18 3.03 6 0.2 0.67 6 0.1 78 6 1 Stenting 2.88 6 0.2 2.63 6 0.2* 29.3 6 2*
Distal 18 1.92 6 0.2 #24 h T 1.99 6 0.2 1.73 6 0.2* 211.4 6 2.7*
Control 11 2.05 6 0.2 ISDN, 3 mg 2.07 6 0.2 1.87 6 0.2 26.8 6 4.8
*p , 0.05: % Elastic Recoil is calculated versus post-PTCA diameter, and % Vasoconstriction is calculated versus
basal diameter. Data presented are mean value 6 SEM. ISDN 5 isosorbide dinitrate; Normal Vessel 5 reference vessel
diameter; % Elastic Recoil 5 percent reduction of diameter measured at the site of dilation; % Vasoconstriction 5
diameter reduction measured at a distal level of the dilated vessel or at a distal level of the control vessel; PTCA 5
percutaneous transluminal coronary angioplasty; T 5 ticlopidine.
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were employed (Immunotech, Marseilles, France). CD62 is a
140-kD component of the platelet alpha granule membrane
and CD63 is a 53-kD lysosomal protein, expressed on the
plasma membrane of platelets that have undergone the release
reaction (26). Immediately after withdrawal, blood samples
were incubated in the catheterization laboratory with FITC-
labeled F(ab)2 fragments of the two monoclonal antibodies for
20 min at room temperature, and after 20 min of incubation
were fixed with 1% formaldehyde. A fluorescence-activated
cell sorter (Facstar, Becton Dickinson) was used for analysis,
which was performed within 24 h after fixation. Results were
expressed as percent of fluorescence-positive platelets (27,28).
Plasma serotonin measurements. Blood was placed into
ice-chilled plastic tubes containing EDTA (5 mmol/liter),
imipramine (5 mmol/liter) PGE1 (10 mmol/liter) and theoph-
ylline (1 mmol/liter) to prevent in vitro platelet activation and
reuptake of serotonin by platelets (13,25). Samples were then
centrifuged at 1,200 g for 20 min at 48C to obtain platelet-poor
plasma, which was subsequently filtered through a 0.20-mm
pore size sterile filter to obtain platelet free plasma. Plasma
was then stored at 2808C until serotonin was determined in
duplicate by radioimmunoassay with commercially available
kits (Serotonin I-125 RIA Test, DDV Biochemie, Marburg,
Germany).
Thrombin-antithrombin (TAT) complexes and prothrom-
bin fragment 112 (F112). TAT complexes form in plasma
when thrombin is neutralized by antithrombin III. F112 forms
in plasma when prothrombin is transformed into thrombin on
the action of activated factor X. Both are considered markers
of thrombin generation. TAT and F112 were measured by
enzyme immunoassays using commercially available, widely
employed and validated kits (29) (Behring Enzygnost Diagnos-
tic Inc.: ELISA-TAT Micro or ELISA-F112 Micro, Marburg,
Germany) on platelet-poor plasma obtained by centrifugation
of citrated blood samples at 1,200 g for 15 min at 48C.
Quantitative angiographic analysis. Catheter stems of
known size and full of contrast medium were used for calibra-
tion: the 35-mm cine frames were analyzed by a geometric and
densitometric quantitative analysis (QCA-ARTREK) de-
scribed by Mancini et al. (30). The frames were automatically
corrected for radiographic pincushion distortion. Diameters
were determined at the narrowest stenotic point under basal
condition, soon after PTCA and 15 min after PTCA to
document the presence of vasoconstriction. The distal segment
corresponds to a peripheral segment of the dilated artery and
of the control nonmanipulated coronary artery, as we (16) and
others (13,23) have described.
Statistical analysis. The results are expressed as mean
value 6 SEM. Two-way analysis of variance for repeated
measures was performed with a commercial package (Sigma
Stat Jandel Scientific). Table 1 presents both absolute and
normalized (%) values. In view of the large interindividual
variability of the absolute values, multiple comparisons be-
tween groups were performed with normalized data. Regres-
sion analysis was performed by the least squares technique. A
p value , 0.05 was considered significant.
Results
Changes in coronary diameters induced by PTCA. Suc-
cessful coronary dilation was achieved in all patients. The data
are shown separately for each group in Table 1. Fifteen
minutes after PTCA, there was significant vasoconstriction in
the dilated and control segments (16). Despite repeated intra-
coronary injection of high doses of nitrates, patients undergo-
ing rotational atherectomy showed marked vasoconstriction
along the dilated and nonmanipulated coronary tree. The
patients with stent implantation had minor but significant
vasoconstriction at the stent level (27.6 6 3%, p , 0.05 vs.
Stent1PTCA) (Table 1). There were no associations between
the degree of vasoconstriction, serotonin levels or the degree
of hemostasis activation.
Coagulation activation. The activated clotting time mea-
sured during the procedures was 391 6 29 s and 397 6 30 s,
respectively, at 10 min and 60 min after heparin injection
(mean heparin given 9,572 6 261 IU).
Mean plasma levels of TAT complexes and F112 (Fig. 2 and
3, respectively) were not significantly different in venous and
arterial baseline samples, indicating that the presence of the
catheter did not activate coagulation with the antithrombotic
treatment employed. In patients not taking ticlopidine or
taking it for ,24 h (Fig. 2 and 3), mean baseline levels of both
measurements were higher than in the comparison group of
healthy persons studied to establish the laboratory reference
values. During the coronary dilation procedures the degree of
coagulation activation did not change significantly, with no
differences found between basal venous and arterial levels of
TAT and F112 as compared with levels immediately after and
10 min after PTCA (Fig. 2 and 3). Significantly higher TAT
levels were found in patients not treated or treated with
ticlopidine for #24 h than in patients given ticlopidine pre-
treatment for $72 h (Fig. 2). Figure 3 also shows that F112
values tended to be higher in the $72-h ticlopidine-treated
groups, but the difference was statistically significant for only a
few samples.
Platelet activation. A status of platelet activation (ex-
pressed as a higher proportion of platelets reacting with both
monoclonal antibodies than in control samples reacting with
F[ab]2-FITC) was observed in patients not treated or treated
with #24-h ticlopidine (p , 0.05 vs. $72-h ticlopidine).
Because platelet activation was similar in groups treated or not
treated with ticlopidine whatever the procedure performed,
the results were pooled and are shown in Figure 4. Patients
treated with $72-h ticlopidine had a degree of platelet activa-
tion similar to that seen in a comparison group of patients
undergoing coronary angiography because of a false positive
effort test and showing a normal coronary artery tree and
negative findings on angina-provocative tests (Fig. 4).
Plasma serotonin levels. Plasma serotonin concentrations
in 68 patients were measured in blood drawn from the
coronary ostium and from the distal coronary artery immedi-
ately after and 10 min after the procedures. Basal coronary
ostium levels and levels obtained immediately after dilation
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procedures did not differ significantly from distal coronary
artery levels. The results are reported in Figure 5. Only
differences between patients treated for $72 h and patients
who received either no ticlopidine or ticlopidine for #24 h
were statistically significant (p , 0.05).
When serotonin levels were plotted against the degree of
elastic recoil and vasoconstriction observed 15 min after the
procedure, we found no significant correlation.
Bleeding complications. There was no bleeding severe
enough to require blood transfusion or local bleeding in
patients during and after the procedures.
Discussion
This study shows that combining ticlopidine (given for
$72 h) with ASA and heparin is more effective than ASA and
heparin alone or ticlopidine given for #24 h in decreasing the
degree of activation of the hemostatic system in patients with
stable or unstable angina even before the performance of
coronary dilation procedures. During the procedures, the
three-drug antithrombotic regimen maintained the hemostasis
activation at the low state achieved before the procedure. In
other studies (12,31,32), ASA and heparin alone were not able
to completely counteract some activation of the coagulation
cascade that leads to acute thrombotic events (1,4,5).
In this study, to evaluate the activation of hemostasis during
coronary dilation procedures, blood was drawn from the distal
Figure 2. Intraprocedure thrombin generation. Bar graphs showing
mean values 6 SEM of thrombin-antithrombin complexes (TAT)
during percutaneous transluminal coronary angioplasty (PTCA) stent
implantation 1 PTCA and rotational ablation (ROTA) 1 PTCA.
C Ost 5 coronary ostium; Dis Art 5 distal coronary artery measure-
ments obtained on blood samples drawn from the coronary ostium and
distal coronary artery immediately after and 10 min after PTCA;
Lab. 5 laboratory; T 5 $72-h ticlopidine; other abbreviations as in
Figure 1.
Figure 3. Intraprocedure thrombin generation. Bar graphs showing
mean values6 SEM of prothrombin fragment 112 (F 112) during the
dilation procedures. Abbreviations as in Figure 2.
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segment of the same artery rather than from the coronary sinus
(13). In this way we avoided 1) mixing of blood derived from
different territories, 2) the confounding effect of a potential
release of serotonin synthesized and metabolized by myocar-
dial cells (33), or 3) active endothelial/platelet reuptake of
serotonin along the coronary microcirculation (34,35).
Behavior of hemostasis measurements. Activation of the
coagulation system was explored by measuring the plasma
concentrations of TAT complexes and F112. Both measure-
ments are sensitive and specific markers of thrombin genera-
tion, which is central not only to coagulation but also to
activation of platelets (36). At all times during the procedures
of coronary dilation, TAT complex levels were much lower in
patients treated than in those not treated with ticlopidine. The
same trend was seen for F112, although the differences were
smaller than those for TAT and at most times were not
statistically significant. The reasons for the differences in
behavior of the two markers of thrombin generation are not
clear, but it has been previously observed (37) that in patients
with ischemic heart disease TAT complexes may be more
sensitive indexes than F112 of the activation of coagulation
induced by thrombolytic agents. In parallel with lesser activa-
tion of the coagulation system, platelets were less activated in
ticlopidine-treated patients, as shown by lower plasma seroto-
nin levels and less exposure on the platelet membranes of the
glycoproteins that indicate the occurrence of the platelet
release reaction.
Rationale for combining two antiplatelet drugs. The ratio-
nale for combining the two antiplatelet agents ASA and
ticlopidine consists in their different mechanisms of action,
which should lead to more drastic suppression of platelet
function. ASA permanently inactivates prostaglandin G/H
synthase, resulting in the suppression of thromboxane-
dependent platelet activation (19). Ticlopidine (22) seems to
Figure 4. Intraprocedure in vivo platelet activation (n 5 74). Bar
graphs showing percent anti-CD62 positive and anti-CD63 platelet
binding. No differences in platelet activation were found in groups
undergoing different procedures; consequently patients have been
grouped according to #24 h or $72 h ticlopidine (T) therapy. Nor
Contr Cor Ost Val 5 normal values, normal coronary artery control
values (see Platelet activation, under Results). Other abbreviations as
in Figures 1 and 2.
Figure 5. Bar graphs showing mean value 6 SEM of plasma serotonin
levels: p- 5 post; p-ROTA 5 postrotational ablation and stent
implantation; other abbreviations as in Figures 1 and 2.
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be involved in three pathways of platelet activation: it inhibits
adenosine diphosphate (ADP)–induced platelet activation
(38), decreases the exposure of fibrinogen receptor on the
platelet membrane and inhibits serotonin release from plate-
lets (39). However, it is an important limitation in the use of
this drug, especially in the course of an acute coronary event
requiring PTCA, that in most persons;72 h is required for the
drug to be fully active (22,39). This is consistent with our
findings that ticlopidine had to be administered for $72 h to
decrease the degree of activation of hemostasis, whereas it was
no more effective than ASA plus heparin alone when admin-
istered for #24 h.
Effect of anti-ischemic treatment. Our patients were also
treated with calcium channel antagonists, which, in experimen-
tal animals, reduce platelet deposition and thrombus forma-
tion and prolong bleeding time (40,41). Nitrous vasodilators
also inhibit platelet activation through complex mechanisms
that might involve increased production of endogenous nitric
oxide and of cyclic guanosine monophosphate (GMP) while
lowering intracellular cytosolic calcium (42,43). Hence, these
treatments may have contributed to the control of hemostasis
activation in our patients.
Serotonin release and vasoconstriction. The combined an-
tithrombotic treatment did not affect the previously observed
vasoconstrictor response that occurs after PTCA (16). When
the protocol included the use of the Rotablator, there was
marked vasoconstriction despite repeated intracoronary injec-
tions of nitrous oxide donors. In a previous report (16) we
hypothesized that the occurrence of such coronary vasocon-
striction, in both the dilated and control vessels was the result
of a sympathetic cardiocardiac excitatory reflex (44,45) elicited
by mechanical manipulation of the vessel. Golino et al. (13)
hypothesized that serotonin release from activated platelets
was responsible for the coronary vasoconstriction, as they
found that it was reduced by the administration of ketanserin.
However, ketanserin also has an alpha1-adrenergic receptor
blocking activity (46). In our study coronary blood concentra-
tions of serotonin were not appreciably increased by angio-
plasty, probably because of our pharmacologic treatment, and
yet the magnitude of coronary vasoconstriction was unmodi-
fied. The occurrence of vasoconstriction along a nonmanipu-
lated vessel seems to reinforce the hypothesis that a sympa-
thetic reflex rather than a released circulating substance is
predominantly involved in this phenomenon.
Clinical implications. The addition of ticlopidine for
$72 h to ASA and heparin markedly reduces the activation of
coagulation and platelets. These findings are consistent with
experimental data suggesting that the inhibition of platelets
with combinations of ASA and ticlopidine may attenuate
factor Xa/Va activity, and, thus, thrombin generation (22,47).
Recently, a clinical trial (48) performed in a large series of
patients demonstrated that this combination of drugs signifi-
cantly reduces acute and subacute occlusions and at the same
time reduces bleeding complications more than do oral anti-
coagulant agents (4,5).
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